ClusterXStem

ClusterXStem is a French biotechnology company specializing in regenerative medicine for the treatment of severe heart failure. Founded on the pioneering research of Professor Philippe Menasché, the company develops therapies based on clusters of cardiovascular progenitor cells derived from human embryonic stem cells (hESCs). Their approach includes both direct cell transplantation and the use of extracellular vesicles (exosomes) to promote cardiac tissue repair and functional recovery. ClusterXStem aims to provide transformative solutions for patients with end-stage heart disease by leveraging the secretome of progenitor cells to induce paracrine healing effects. The company is backed by Truffle Capital and is headquartered in Paris, France.